ANAPTYSBIO, INC. Revenue
ANAPTYSBIO, INC. (ANAB) reported Revenue of $53.04 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-09-21
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $27.49M, a 23.47% increase year-over-year.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $25.56M, a 7.98% decline year-over-year.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $108.25M, a 151.08% increase year-over-year.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $76.32M, a 154.26% increase year-over-year.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $234.60M, a 157.01% increase from fiscal 2024.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $91.28M, a 432.03% increase from fiscal 2023.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $17.16M, a 66.78% increase from fiscal 2022.
- ANAPTYSBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $10.29M, a 83.72% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.49M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $53.04M 10-KT · filed 2026-09-21 | $161.29M derived: sum of 3 quarters · filed 2026-09-21 | $237.61M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | $25.56M 10-Q · filed 2026-05-12 | $133.81M derived: sum of 2 quarters · filed 2026-09-21 | $210.13M derived: sum of 3 quarters · filed 2026-09-21 | $232.39M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $108.25M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $184.57M derived: sum of 2 quarters · filed 2026-09-21 | $206.83M derived: sum of 3 quarters · filed 2026-09-21 | $234.60M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $76.32M 10-Q · filed 2025-11-04 | $98.58M derived: sum of 2 quarters · filed 2025-11-04 | $126.35M 10-Q · filed 2025-11-04 | $169.47M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | $22.26M 10-Q · filed 2025-08-06 | $50.03M 10-KT · filed 2026-09-21 | $93.15M derived: sum of 3 quarters · filed 2026-09-21 | $123.16M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | $27.77M 10-Q · filed 2026-05-12 | $70.88M derived: sum of 2 quarters · filed 2026-09-21 | $100.90M derived: sum of 3 quarters · filed 2026-09-21 | $111.87M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | $43.11M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $73.13M derived: sum of 2 quarters · filed 2026-09-21 | $84.10M derived: sum of 3 quarters · filed 2026-09-21 | $91.28M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $30.02M 10-Q · filed 2025-11-04 | $40.99M derived: sum of 2 quarters · filed 2025-11-04 | $48.17M 10-Q · filed 2025-11-04 | $57.17M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $10.97M 10-Q · filed 2025-08-06 | $18.15M 10-Q · filed 2025-08-06 | $27.16M derived: sum of 3 quarters · filed 2026-03-03 | $30.47M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $7.18M 10-Q · filed 2025-05-05 | $16.18M derived: sum of 2 quarters · filed 2026-03-03 | $19.50M derived: sum of 3 quarters · filed 2026-03-03 | $22.96M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $12.32M derived: sum of 2 quarters · filed 2026-03-03 | $15.78M derived: sum of 3 quarters · filed 2026-03-03 | $17.16M 10-K · filed 2026-03-03 |
| 2023-09-30 | $3.32M 10-Q · filed 2024-11-05 | $6.78M derived: sum of 2 quarters · filed 2024-11-05 | $8.15M 10-Q · filed 2024-11-05 | $14.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.46M 10-Q · filed 2024-08-05 | $4.83M 10-Q · filed 2024-08-05 | $11.64M derived: sum of 3 quarters · filed 2025-02-27 | $12.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.37M 10-Q · filed 2024-05-09 | $8.18M derived: sum of 2 quarters · filed 2025-02-27 | $9.47M derived: sum of 3 quarters · filed 2025-02-27 | $10.69M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $8.10M derived: sum of 2 quarters · filed 2025-02-27 | $9.32M derived: sum of 3 quarters · filed 2025-02-27 | $10.29M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.29M 10-Q · filed 2023-11-02 | $2.51M derived: sum of 2 quarters · filed 2023-11-02 | $3.48M 10-Q · filed 2023-11-02 | $4.49M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $1.22M 10-Q · filed 2023-08-07 | $2.19M 10-Q · filed 2023-08-07 | $3.20M derived: sum of 3 quarters · filed 2024-03-11 | $24.09M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $970.00K 10-Q · filed 2023-05-11 | $1.98M derived: sum of 2 quarters · filed 2024-03-11 | $22.87M derived: sum of 3 quarters · filed 2024-03-11 | $52.90M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $21.90M derived: sum of 2 quarters · filed 2024-03-11 | $51.93M derived: sum of 3 quarters · filed 2024-03-11 | $63.17M 10-K · filed 2024-03-11 |
| 2021-09-30 | $20.89M 10-Q · filed 2022-11-08 | $50.92M derived: sum of 2 quarters · filed 2022-11-08 | $62.16M 10-Q · filed 2022-11-08 | $122.16M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $30.03M 10-Q · filed 2022-08-08 | $41.27M 10-Q · filed 2022-08-08 | $101.27M derived: sum of 3 quarters · filed 2023-03-01 | $101.27M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $11.25M 10-Q · filed 2022-05-04 | $71.25M derived: sum of 2 quarters · filed 2023-03-01 | $71.25M derived: sum of 3 quarters · filed 2023-03-01 | $71.25M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $60.00M derived: sum of 2 quarters · filed 2023-03-01 | $60.00M derived: sum of 3 quarters · filed 2023-03-01 | $75.00M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $15.00M 10-Q · filed 2021-11-04 | $18.00M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | $15.00M 10-Q · filed 2021-08-09 | $18.00M derived: sum of 3 quarters · filed 2022-03-07 | $18.00M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-03-31 | $15.00M 10-Q · filed 2021-05-04 | $18.00M derived: sum of 2 quarters · filed 2022-03-07 | $18.00M derived: sum of 3 quarters · filed 2022-03-07 | $23.00M derived: sum of 4 quarters · filed 2022-03-07 |
| 2019-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $3.00M derived: sum of 2 quarters · filed 2022-03-07 | $8.00M derived: sum of 3 quarters · filed 2022-03-07 | $8.00M 10-K · filed 2022-03-07 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | $5.00M derived: sum of 2 quarters · filed 2020-11-04 | $5.00M 10-Q · filed 2020-11-04 | $5.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $5.00M 10-Q · filed 2020-08-10 | $5.00M 10-Q · filed 2020-08-10 | $5.00M derived: sum of 3 quarters · filed 2021-02-25 | $10.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $5.00M derived: sum of 3 quarters · filed 2021-02-25 | $5.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.00M derived: sum of 2 quarters · filed 2021-02-25 | $5.00M derived: sum of 3 quarters · filed 2021-02-25 | $5.00M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.00M 10-Q · filed 2019-11-08 | $5.00M derived: sum of 2 quarters · filed 2019-11-08 | $5.00M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $10.00M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |